hsa-mir-127	Colonic Neoplasms	17355635	Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene.
hsa-mir-127	Prostatic Neoplasms	17355635	Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene.
hsa-mir-127	Urinary Bladder Neoplasms	17355635	Human miR-127 is embedded in a CpG island and is silenced in several human cancers including bladder, prostate and colon cancer and has been suggested to play a role as a possible tumour suppressor gene.
hsa-mir-29b-1	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
hsa-mir-29a	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
hsa-mir-29c	Lung Neoplasms	17890317	mir-29 family (29a,b,c) reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
hsa-mir-126	Neoplasms	19116145	miR-126: a tumor supressor: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7
hsa-mir-34a	Neoplasms	18719384	miR-34a: inactivation, Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
hsa-mir-34b	Neoplasms	18768788	miR-34b: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
hsa-mir-34c	Neoplasms	18768788	miR-34c: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
hsa-mir-9-1	Neoplasms	18768788	miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
hsa-mir-9-2	Neoplasms	18768788	miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
hsa-mir-9-3	Neoplasms	18768788	miR-9: were found to undergo specific hypermethylation-associated silencing in cancer cells compared with normal tissues
hsa-mir-124-1	Myelodysplastic Syndromes	20448201	miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome
hsa-mir-124-2	Carcinoma, Hepatocellular	19843643	miR-124:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
hsa-mir-124-2	Myelodysplastic Syndromes	20448201	miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome
hsa-mir-124-3	Carcinoma, Hepatocellular	19843643	miR-124:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
hsa-mir-124-3	Myelodysplastic Syndromes	20448201	miRNA-124:Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome
hsa-mir-137	Carcinoma, Squamous Cell	20197299	miR-137:MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index
hsa-mir-148a	Lung Neoplasms	20431052	miR-148a:The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis
hsa-mir-152	Carcinoma, Hepatocellular	20578129	microRNA-152:a tumor-suppressive role of miR-152 in the epigenetic aberration of HBV-related HCC
hsa-mir-203	Carcinoma, Hepatocellular	19843643	miR-203:miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
hsa-mir-212	Stomach Neoplasms	20020497	miR-212:miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer
hsa-mir-193b	Prostatic Neoplasms	20073067	miR-193b:miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer
hsa-mir-181c	Stomach Neoplasms	20080834	miR-181c:Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis.
hsa-mir-27a	Pancreatic Neoplasms	20488920	microRNA-27a:Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a
hsa-mir-9-1	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-9-2	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-9-3	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-149	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-210	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-212	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-328	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-503	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-1224	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-1227	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-1229	Urinary Bladder Neoplasms	21138856	hypermethylation was more frequent and dense in CpG shores than islands
hsa-mir-373	Cholangiocarcinoma	21165562	Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar Cholangiocarcinoma.
hsa-mir-126	Lupus Erythematosus, Systemic	21165896	MicroRNA-126 regulates DNA methylation in CD4(+) T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1.
hsa-mir-34b	Stomach Neoplasms	21213213	upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared with adjacent normal tissues, and their methylation status correlated inversely with their expression patterns.
hsa-mir-129-2	Stomach Neoplasms	21213213	upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared with adjacent normal tissues, and their methylation status correlated inversely with their expression patterns.
hsa-mir-34a	Colorectal Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34a	Pancreatic Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34a	Breast Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34a	Urinary Bladder Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34a	Carcinoma, Renal Cell	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34b	Colorectal Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34b	Pancreatic Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34b	Breast Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34b	Urinary Bladder Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34b	Carcinoma, Renal Cell	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34c	Colorectal Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34c	Pancreatic Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34c	Breast Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34c	Urinary Bladder Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34c	Carcinoma, Renal Cell	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34a	Ovarian Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34a	Sarcoma	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34b	Ovarian Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34b	Sarcoma	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34c	Ovarian Neoplasms	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-34c	Sarcoma	21225432	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
hsa-mir-29b-1	Atherosclerosis	21266537	OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases.
hsa-mir-29b-2	Atherosclerosis	21266537	OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases.
hsa-mir-335	Breast Neoplasms	21289068	MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer.
hsa-mir-200b	Neoplasms	21292642	Depletion of miR-200 in arsenite-transformed cells involved induction of the EMT-inducing transcription factors ZEB1 (zinc-finger E-box-binding homeobox factor 1) and ZEB2 and increased methylation of miR-200 promoters.
hsa-mir-203	Leukemia, Myeloid, Acute	21323860	The frequent hsa-miR-203 methylation in lymphoid malignancies suggested a pathogenetic role of hsa-miR-203 methylation.
hsa-mir-1-1	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-1-1	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-1-1	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-1	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-1	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-1	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-2	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-2	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-2	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-3	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-3	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-124-3	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-148a	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-148a	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-148a	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-152	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-152	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-152	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-18b	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-18b	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-18b	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-200a	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-200a	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-200a	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-208a	Colorectal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-208a	Gastrointestinal Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-208a	Endometrial Neoplasms	21327300	Compared with the respective normal tissues, the predominant alteration in tumor tissues was increased methylation for the miRNAs 1-1, 124a-1, 124a-2, 124a-3, 148a, 152, and 18b; decreased methylation for 200a and 208a;
hsa-mir-145	Prostatic Neoplasms	21349819	this is the first report documenting that downregulation of miR-145 is through DNA methylation and p53 mutation pathways in prostate cancer.
hsa-mir-34b	Carcinoma, Non-Small-Cell Lung	21383543	DNA hypermethylation of microRNA-34b/c has prognostic value for stage â…?non-small cell lung cancer.
hsa-mir-34c	Carcinoma, Non-Small-Cell Lung	21383543	DNA hypermethylation of microRNA-34b/c has prognostic value for stage â…?non-small cell lung cancer.
hsa-mir-199a-1	Testicular Neoplasms	21383689	PODXL is a downstream effector mediating the action of miR199a-5p. This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy.
hsa-mir-199a-2	Testicular Neoplasms	21383689	PODXL is a downstream effector mediating the action of miR199a-5p. This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy.
hsa-mir-193a	Leukemia, Myeloid, Acute	21399664	MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.
hsa-mir-137	Carcinoma, Squamous Cell	21425146	MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck.
hsa-mir-203	Lymphoma	21454413	Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis.
hsa-mir-203	Uterine Cervical Neoplasms	21461574	hypermethylation of miR-124a and miR-203 in the precursor lesions compared to the control samples
hsa-mir-181a-1	Carcinoma, Hepatocellular	21464043	HBx promotes "stemness" by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
hsa-mir-181a-2	Carcinoma, Hepatocellular	21464043	HBx promotes "stemness" by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
hsa-mir-181b-1	Carcinoma, Hepatocellular	21464043	HBx promotes "stemness" by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
hsa-mir-181b-2	Carcinoma, Hepatocellular	21464043	HBx promotes "stemness" by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
hsa-mir-181c	Carcinoma, Hepatocellular	21464043	HBx promotes "stemness" by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
hsa-mir-181d	Carcinoma, Hepatocellular	21464043	HBx promotes "stemness" by activating {beta}-catenin and epigenetic up-regulation of miR-181, both of which target EpCAM.
hsa-mir-375	Esophageal Neoplasms	21533613	Epigenetic Silencing of MicroRNA-375 Regulates PDK1 Expression in Esophageal Cancer
hsa-mir-375	Esophageal Neoplasms	21533613	Epigenetic Silencing of MicroRNA-375 Regulates PDK1 Expression in Esophageal Cancer.
hsa-mir-24-1	Lymphoma	21544199	miR-124-1 is epigenetically inactivated in Haematological Malignancies.
hsa-mir-24-1	Multiple Myeloma	21544199	miR-124-1 is epigenetically inactivated in Haematological Malignancies.
hsa-mir-24-1	Leukemia, Myeloid, Acute	21544199	miR-124-1 is epigenetically inactivated in Haematological Malignancies.
hsa-mir-34a	Esophageal Neoplasms	21547903	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
hsa-mir-34b	Esophageal Neoplasms	21547903	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
hsa-mir-34c	Esophageal Neoplasms	21547903	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
hsa-mir-129-2	Esophageal Neoplasms	21547903	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
hsa-mir-34a	Carcinoma, Squamous Cell	21547903	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
hsa-mir-34b	Carcinoma, Squamous Cell	21547903	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
hsa-mir-34c	Carcinoma, Squamous Cell	21547903	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
hsa-mir-129-2	Carcinoma, Squamous Cell	21547903	The methylation ratio of miR-34a, miR-34b/c and miR-129-2 is 66.7%(36/54), 40.7%(22/54), and 96.3%(52/54) respectively in ESCC, which are significantly higher than that in corresponding non-tumor tissues(p<0.01).
hsa-mir-10b	Stomach Neoplasms	21562367	miR-10b methylation may be a useful molecular biomarker for assessing the risk of gastric cancer development, and modulation of miR-10b may represent a therapeutic approach for treating gastric cancer.
hsa-mir-132	Pancreatic Neoplasms	21665894	Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development.
hsa-mir-345	Colorectal Neoplasms	21665895	MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer.
hsa-mir-34b	Mesothelioma	21673066	Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma.
hsa-mir-34c	Mesothelioma	21673066	Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma.
hsa-mir-221	Breast Neoplasms	21673316	TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.
hsa-mir-196a-2	Carcinoma, Hepatocellular	21692953	The CC genotype of the miR-196a-2 rs11614913 polymorphism is associated with increased risk of HCC development in this Turkish population.
hsa-mir-34b	Carcinoma, Non-Small-Cell Lung	21702040	mir-34b and mir-126 were silenced by DNA methylation.
hsa-mir-126	Carcinoma, Non-Small-Cell Lung	21702040	mir-34b and mir-126 were silenced by DNA methylation.
hsa-mir-143	Precursor Cell Lymphoblastic Leukemia-Lymphoma	21706045	Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression.
hsa-mir-203	Multiple Myeloma	21707582	MIR203 is epigeneticlly silenced in multiple myeloma.
hsa-mir-373	Colorectal Neoplasms	21785829	Epigenetic silencing of microRNA-373 plays an important role in regulating cell proliferation in colon cancer.
hsa-mir-200a	Carcinoma, Hepatocellular	21837748	The histone deacetylase 4/Sp1/miR-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma.
hsa-mir-152	Endometrial Neoplasms	21868754	miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer.
hsa-mir-34b	Stomach Neoplasms	21914401	The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma.
hsa-mir-34c	Stomach Neoplasms	21914401	The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma.
hsa-mir-124-1	Stomach Neoplasms	21914401	The hypermethylation of miRNA-34b/c and miRNA-124a gene promoters may play a crucial role in the occurrence and development of gastric carcinoma.
hsa-mir-9-3	Carcinoma, Non-Small-Cell Lung	21917081	The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit.
hsa-mir-124-2	Carcinoma, Non-Small-Cell Lung	21917081	The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit.
hsa-mir-124-3	Carcinoma, Non-Small-Cell Lung	21917081	The methylation of mir-9-3, -124-2, and -124-3 was individually associated with an advanced T factor independently of age, sex, and smoking habit.
hsa-mir-139	Stomach Neoplasms	21925125	HER2 Interacts with CD44 to Upregulate CXCR4 via Epigenetic Silencing of microRNA-139 in Gastric Cancer Cells.
hsa-mir-9-1	Stomach Neoplasms	21931274	In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment.
hsa-mir-9-2	Stomach Neoplasms	21931274	In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment.
hsa-mir-9-3	Stomach Neoplasms	21931274	In this study, we demonstrate that three independent genetic loci encoding for miR-9 (miR-9-1, miR-9-2 and miR-9-3) are simultaneously modified by DNA methylation in gastric cancer cells. Methylation-mediated silencing of these three miR-9 genes can be reactivated in gastric cancer cells through 5-Aza-dC treatment.
hsa-mir-34b	Stomach Neoplasms	21960261	The methylation-silenced expression of the miRNA could be reactivated in gastric cancer cells by treatment with demethylating drugs in a time-dependent manner.Analysis of the methylation status of these miRNAs showed that the upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared to adjacent normal tissues, and their methylation status correlated inversely with their expression patterns. The expression of miR-34b and miR-129-3p was downregulated by DNA hypermethylation in primary gastric cancers, and the low expression was associated with poor clinicopathological features.
hsa-mir-129-2	Stomach Neoplasms	21960261	The methylation-silenced expression of the miRNA could be reactivated in gastric cancer cells by treatment with demethylating drugs in a time-dependent manner.Analysis of the methylation status of these miRNAs showed that the upstream CpG-rich regions of mir-34b and mir-129-2 are frequently methylated in gastric cancer tissues compared to adjacent normal tissues, and their methylation status correlated inversely with their expression patterns. The expression of miR-34b and miR-129-3p was downregulated by DNA hypermethylation in primary gastric cancers, and the low expression was associated with poor clinicopathological features.
hsa-let-7e	Breast Neoplasms	21969366	Jumonji/Arid1 B (JARID1B) promotes breast tumor cell cycle progression through epigenetic repression of micro RNA let-7e.
hsa-mir-191	Carcinoma, Hepatocellular	21969817	Hypomethylation of the hsa-miR-191 Locus Causes High Expression of hsa-miR-191 and Promotes the Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma.
hsa-mir-34b	Small Cell Lung Carcinoma	22047961	Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.
hsa-mir-34c	Small Cell Lung Carcinoma	22047961	Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.
hsa-mir-34b	Neoplasms	22082000	miR-34b/c were homozygously methylated in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with miR silencing, and 5-aza-2'-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was methylated in one patient and none had methylation of miR-124-1.
hsa-mir-34c	Neoplasms	22082000	miR-34b/c were homozygously methylated in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with miR silencing, and 5-aza-2'-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was methylated in one patient and none had methylation of miR-124-1.
hsa-mir-663a	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	22089542	The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation.
hsa-mir-369	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	22089542	The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation.
hsa-mir-615	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	22089542	The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation.
hsa-mir-410	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	22089542	The CpG islands in the upstream regions of miR-663, miR-369, miR-615, and miR-410, and promoter activity was detected in the upstream region of pre-miR-663. We found that a decrease in methylation of a CpG island could up-regulate the expression of miR-663, suggesting that miR-663 could be regulated by DNA methylation.
hsa-mir-15a	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
hsa-mir-16-1	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
hsa-mir-16-2	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
hsa-mir-29b-1	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
hsa-mir-29b-2	Leukemia, Lymphocytic, Chronic, B-Cell	22096249	Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia.
hsa-mir-193a	Carcinoma, Hepatocellular	22117060	DNA methylation regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via SRSF2.
hsa-mir-375	Mouth Neoplasms	22132151	MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
hsa-mir-127	Mouth Neoplasms	22132151	MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
hsa-mir-137	Mouth Neoplasms	22132151	MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
hsa-mir-200a	Mouth Neoplasms	22132151	MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
hsa-mir-200c	Mouth Neoplasms	22132151	MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
hsa-mir-141	Mouth Neoplasms	22132151	MiR-375 is repressed and miR-127 activated in OSCC, and we confirm previous reports of miR-137 hypermethylation in oral cancer. The miR-200 s/miR-205 were epigenetically activated in tumors vs normal tissues, but repressed in the absence of DNA hypermethylation specifically in CD44(high) oral CSCs. Aberrant miR-375 and miR-200a expression and miR-200c-141 methylation could be detected in and distinguish OSCC patient oral rinse and saliva from healthy volunteers.
hsa-mir-9-1	Carcinoma, Squamous Cell	22133638	Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas.
hsa-mir-9-3	Carcinoma, Squamous Cell	22133638	Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas.
hsa-mir-148a	Stomach Neoplasms	22167392	MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer.
hsa-mir-200b	Breast Neoplasms	22231446	Methylation of functional promoters of the Hsa-mir-200b is associated with metastasis or hormone receptor status in advanced breast cancer.
hsa-mir-519d	Carcinoma, Hepatocellular	22262409	In hepatocellular carcinoma miR-519d is upregulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.
hsa-mir-9-3	Carcinoma, Non-Small-Cell Lung	22282464	Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non-Small Cell Lung Cancers.
hsa-mir-193a	Carcinoma, Non-Small-Cell Lung	22282464	Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non-Small Cell Lung Cancers.
hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	hsa-mir-31	Breast Neoplasms	22289355	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.
hsa-mir-152	Atherosclerosis	22295098	MicroRNA-152 mediates DNMT1-regulated DNA methylation in the estrogen receptor α gene.
hsa-mir-17	Colorectal Neoplasms	22308110	Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
hsa-mir-18a	Colorectal Neoplasms	22308110	Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
hsa-mir-19a	Colorectal Neoplasms	22308110	Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
hsa-mir-20a	Colorectal Neoplasms	22308110	Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
hsa-mir-19b-1	Colorectal Neoplasms	22308110	Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
hsa-mir-92a-1	Colorectal Neoplasms	22308110	Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
hsa-mir-132	Prostatic Neoplasms	22310291	DNA methylation silences miR-132 in prostate cancer.
hsa-mir-139	Carcinoma, Hepatocellular	22370893	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
hsa-mir-125b-1	Carcinoma, Hepatocellular	22370893	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
hsa-mir-125b-2	Carcinoma, Hepatocellular	22370893	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
hsa-mir-101-1	Carcinoma, Hepatocellular	22370893	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
hsa-let-7c	Carcinoma, Hepatocellular	22370893	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
hsa-mir-200b	Carcinoma, Hepatocellular	22370893	Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs (miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b) to promote liver cancer metastasis.
hsa-mir-203	Breast Neoplasms	22393463	Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells.
hsa-mir-224	Carcinoma, Hepatocellular	22459148	MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms.
hsa-mir-7-1	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
hsa-mir-7-2	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
hsa-mir-7-3	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
hsa-mir-218-1	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
hsa-mir-218-2	Breast Neoplasms	22705304	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.
hsa-mir-1-1	Colorectal Neoplasms	22766685	Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer.
hsa-mir-133a-1	Colorectal Neoplasms	22766685	Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer.
hsa-mir-133a-2	Colorectal Neoplasms	22766685	Silencing of miR-1-1 and miR-133a-2 cluster expression by DNA hypermethylation in colorectal cancer.
hsa-mir-340	Neuroblastoma	22797059	miR-340 is upregulated by demethylation of an upstream genomic region that occurs during the process of neuroblastoma cell differentiation induced by all-trans retinoic acid (ATRA).
hsa-mir-1256	Prostatic Neoplasms	22805767	Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.
hsa-mir-29a	Prostatic Neoplasms	22805767	Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.
hsa-mir-124-1	Cholangiocarcinoma	22819820	Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
hsa-mir-124-2	Cholangiocarcinoma	22819820	Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
hsa-mir-149	Colorectal Neoplasms	22821729	SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer.
hsa-mir-205	Prostatic Neoplasms	22869146	Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer.
hsa-mir-141	Esophageal Neoplasms	22921431	Inhibition of SOX17 by MicroRNA-141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer.
hsa-mir-31	Melanoma	22948084	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma.
hsa-mir-29a	Lymphoma, B-Cell	23079660	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas
hsa-mir-29b-1	Lymphoma, B-Cell	23079660	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas
hsa-mir-29b-2	Lymphoma, B-Cell	23079660	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas
hsa-mir-200a	Breast Neoplasms	23112837	the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer
hsa-mir-200b	Breast Neoplasms	23112837	the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer
hsa-mir-200c	Breast Neoplasms	23112837	the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer
hsa-mir-149	Colorectal Neoplasms	23115050	Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer
hsa-mir-137	Mouth Neoplasms	23121285	MicroRNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma
hsa-mir-101-1	Hepatitis B	23124077	miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A
hsa-mir-101-2	Hepatitis B	23124077	miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A
hsa-mir-29b-1	Lupus Erythematosus, Systemic	23142053	MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1
hsa-mir-29b-2	Lupus Erythematosus, Systemic	23142053	MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1
hsa-mir-34b	Prostatic Neoplasms	23147995	miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways
hsa-mir-29b-1	Leukemia, Myeloid, Acute	23178755	Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
hsa-mir-29b-2	Leukemia, Myeloid, Acute	23178755	Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
hsa-mir-211	Glioma	23183822	Epigenetic Regulation of miRNA-211 by MMP-9 Governs Glioma Cell Apoptosis,Chemosensitivity and Radiosensitivity
hsa-mir-200a	Carcinoma, Hepatocellular	23222811	Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma
hsa-mir-200b	Carcinoma, Hepatocellular	23222811	Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma
hsa-mir-200c	Carcinoma, Hepatocellular	23222811	Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma
hsa-mir-193a	Leukemia, Myeloid, Acute	23223432	Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21)acute myeloid leukemia by activating the PTEN/PI3K signal pathway
hsa-mir-335	Carcinoma, Hepatocellular	23229728	Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma
hsa-mir-31	Prostatic Neoplasms	23233736	Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression
hsa-mir-34a	Colonic Neoplasms	23243217	Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and beta-Catenin Predicts Distant Metastasis of Colon Cancer
hsa-mir-124-1	Carcinoma, Renal Cell	23321515	Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma
hsa-mir-124-2	Carcinoma, Renal Cell	23321515	Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma
hsa-mir-124-3	Carcinoma, Renal Cell	23321515	Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma
hsa-mir-195	Stomach Neoplasms	23333942	MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer
hsa-mir-378a	Stomach Neoplasms	23333942	MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer
hsa-mir-124-1	Pancreatic Neoplasms	23334332	Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1
hsa-mir-124-2	Pancreatic Neoplasms	23334332	Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1
hsa-mir-124-3	Pancreatic Neoplasms	23334332	Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1
hsa-mir-129-2	Carcinoma, Hepatocellular	23402613	Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC
hsa-mir-124a-2	Carcinoma, Renal Cell	23755536	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
hsa-mir-124a-3	Carcinoma, Renal Cell	23755536	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
hsa-mir-9-1	Carcinoma, Renal Cell	23755536	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
hsa-mir-9-3	Carcinoma, Renal Cell	23755536	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
hsa-mir-34b	Carcinoma, Renal Cell	23755536	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
hsa-mir-34c	Carcinoma, Renal Cell	23755536	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
hsa-mir-129-2	Carcinoma, Renal Cell	23755536	The frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue
hsa-mir-432	HPV Infection	23732000	We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
hsa-mir-1286	HPV Infection	23732000	We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
hsa-mir-641	HPV Infection	23732000	We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
hsa-mir-1290	HPV Infection	23732000	We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
hsa-mir-1287	HPV Infection	23732000	We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
hsa-mir-95	HPV Infection	23732000	We found hypermethylation of miR-432, miR-1286, miR-641, miR-1290, miR-1287 and miR-95 may have some relationship with HPV infection in cervical cell lines.
hsa-mir-129-1	Carcinoma, Hepatocellular	23580407	Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma
hsa-mir-129-2	Carcinoma, Hepatocellular	23580407	Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma
hsa-mir-200	Breast Neoplasms	23525011	Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem cell-like state